Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Computational Strategies Targeting Inhibition of Helicobacter pylori and Cryptococcus neoformans Ureases

Author(s): Marciéli Fabris, Nailton M. Nascimento-Júnior, Marcelle L.F. Bispo* and Priscila G. Camargo*

Volume 29, Issue 10, 2023

Published on: 04 April, 2023

Page: [777 - 792] Pages: 16

DOI: 10.2174/1381612829666230329122902

Price: $65

Abstract

Helicobacter pylori and Cryptococcus ssp. are pathogenic ureolytic microorganisms that cause several disorders in the host organism and, in severe cases, lead to death. Both infections have the urease enzyme as a key virulence factor since they use its ability to produce ammonia to soften the inhospitable pH to which they are subjected. In this review, we describe two ureases as possible molecular targets for drug discovery and provide insights for developing potent inhibitors against ureases from these pathogenic microorganisms through computer-aided drug discovery approaches, such as structure-based drug design (SBDD) and structure-activity relationship (SAR). The SAR studies have indicated several essential subunits and groups to be present in urease inhibitors that are critical for inhibitory activity against H. pylori or Cryptococcus spp. Since the threedimensional structure of C. neoformans urease has yet to be determined experimentally, the plant urease of Canavalia ensiformis was used in this study due to its structural similarity. Therefore, in the SBDD context, FTMap and FTSite analyses were performed to reveal characteristics of the urease active sites in two protein data bank files (4H9M, Canavalia ensiformis, and 6ZJA, H. pylori). Finally, a docking-based analysis was performed to explore the best inhibitors described in the literature to understand the role of the ligand interactions with the key residues in complex ligand-urease stabilization, which can be applied in the design of novel bioactive compounds.

Keywords: Drug discovery, urease inhibitors, structure-activity relationship, molecular docking, Canavalia ensiformis, ureolytic microorganisms, cryptococcosis, virulence factor.

« Previous Next »
[1]
Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19(3): 449-90.
[http://dx.doi.org/10.1128/CMR.00054-05] [PMID: 16847081]
[2]
Cho J, Prashar A, Jones NL, Moss SF. Helicobacter pylori Infection. Gastroenterol Clin North Am 2021; 50(2): 261-82.
[http://dx.doi.org/10.1016/j.gtc.2021.02.001] [PMID: 34024441]
[3]
Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017; 153(2): 420-9.
[http://dx.doi.org/10.1053/j.gastro.2017.04.022] [PMID: 28456631]
[4]
Alexander SM, Retnakumar RJ, Chouhan D, et al. Helicobacter pylori in human stomach: The inconsistencies in clinical outcomes and the probable causes. Front Microbiol 2021; 12: 713955.
[http://dx.doi.org/10.3389/fmicb.2021.713955] [PMID: 34484153]
[5]
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112(2): 212-39.
[http://dx.doi.org/10.1038/ajg.2016.563] [PMID: 28071659]
[6]
Diaconu S, Predescu A, Moldoveanu A, Pop CS. Fierbințeanu-Braticevici C. Helicobacter pylori infection: old and new. J Med Life 2017; 10(2): 112-7.
[PMID: 28616085]
[7]
Huang X, Liu Y, Lin Z, et al. Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China. PLoS One 2021; 16(9): e0256225.
[http://dx.doi.org/10.1371/journal.pone.0256225] [PMID: 34473713]
[8]
Fung HB, Doan TL. Tinidazole: A nitroimidazole antiprotozoal agent. Clin Ther 2005; 27(12): 1859-84.
[http://dx.doi.org/10.1016/j.clinthera.2005.12.012] [PMID: 16507373]
[9]
Gushiken AC, Saharia KK, Baddley JW. Cryptococcosis. Infect Dis Clin North Am 2021; 35(2): 493-514.
[http://dx.doi.org/10.1016/j.idc.2021.03.012] [PMID: 34016288]
[10]
Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. Med Mycol 2019; 57(2): 133-50.
[http://dx.doi.org/10.1093/mmy/myy086] [PMID: 30329097]
[11]
Zaragoza O. Basic principles of the virulence of Cryptococcus. Virulence 2019; 10(1): 490-501.
[http://dx.doi.org/10.1080/21505594.2019.1614383] [PMID: 31119976]
[12]
Fu MS, Coelho C, De Leon-Rodriguez CM, et al. Cryptococcus neoformans urease affects the outcome of intracellular pathogenesis by modulating phagolysosomal pH. PLoS Pathog 2018; 14(6): e1007144.
[http://dx.doi.org/10.1371/journal.ppat.1007144] [PMID: 29906292]
[13]
World Health Organization. Guidelines on the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection; World Health Organization: Geveva, Switzerland. 2018.
[14]
Baddley JW, Forrest GN. Cryptococcosis in solid organ transplantation-guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant 2019; 33(9): e13543.
[http://dx.doi.org/10.1111/ctr.13543] [PMID: 30900315]
[15]
Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50(3): 291-322.
[http://dx.doi.org/10.1086/649858] [PMID: 20047480]
[16]
Li Y, Zou M, Yin J, Liu Z, Lu B. Microbiological, epidemiological, and clinical characteristics of patients with cryptococcal meningitis at a tertiary hospital in China: A 6-year retrospective analysis. Front Microbiol 2020; 11: 1837.
[http://dx.doi.org/10.3389/fmicb.2020.01837] [PMID: 32849436]
[17]
Moeng LR, Milburn J, Jarvis JN, Lawrence DS. HIV-associated cryptococcal meningitis: A review of novel short-course and oral therapies. Curr Treat Options Infect Dis 2020; 12(4): 422-37.
[http://dx.doi.org/10.1007/s40506-020-00239-0]
[18]
Wirth F, de Azevedo MI, Pilla C, Aquino VR, Neto GW, Goldani LZ. Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis. Med Mycol 2018; 56(3): 257-62.
[http://dx.doi.org/10.1093/mmy/myx054] [PMID: 28992308]
[19]
Krajewska B, Ureases I. Functional, catalytic and kinetic properties: A review. J Mol Catal, B Enzym 2009; 59(1-3): 9-21.
[http://dx.doi.org/10.1016/j.molcatb.2009.01.003]
[20]
Lippard SJ. At last the crystal structure of urease. Science 1995; 268(5213): 996-7.
[21]
Benini S, Rypniewski WR, Wilson KS, Miletti S, Ciurli S, Mangani S. A new proposal for urease mechanism based on the crystal structures of the native and inhibited enzyme from Bacillus pasteurii: why urea hydrolysis costs two nickels. Structure 1999; 7(2): 205-16.
[http://dx.doi.org/10.1016/S0969-2126(99)80026-4] [PMID: 10368287]
[22]
Stumpfe D, Bajorath J. Recent developments in SAR visualization. MedChemComm 2016; 7(6): 1045-55.
[http://dx.doi.org/10.1039/C6MD00108D]
[23]
Yang Z, Tian Y, Kong Y, Zhu Y, Yan A. Classification of JAK1 inhibitors and SAR research by machine learning methods. Artif Intell Life Sci 2022; 2: 100039.
[http://dx.doi.org/10.1016/j.ailsci.2022.100039]
[24]
Kataria R, Khatkar A. In-silico designing, ADMET analysis, synthesis and biological evaluation of novel derivatives of diosmin against urease protein and Helicobacter pylori Bacterium. Curr Top Med Chem 2019; 19(29): 2658-75.
[http://dx.doi.org/10.2174/1568026619666191114123452] [PMID: 31724503]
[25]
Li WY, Ni WW, Ye YX, et al. N-monoarylacetothioureas as potent urease inhibitors: Synthesis, SAR, and biological evaluation. J Enzyme Inhib Med Chem 2020; 35(1): 404-13.
[http://dx.doi.org/10.1080/14756366.2019.1706503] [PMID: 31880473]
[26]
Liu Q, Shi WK, Ren SZ, et al. Arylamino containing hydroxamic acids as potent urease inhibitors for the treatment of Helicobacter pylori infection. Eur J Med Chem 2018; 156: 126-36.
[http://dx.doi.org/10.1016/j.ejmech.2018.06.065] [PMID: 30006158]
[27]
Mamidala R, Bhimathati SRS, Vema A. Discovery of novel dihydropyrimidine and hydroxamic acid hybrids as potent Helicobacter pylori urease inhibitors. Bioorg Chem 2021; 114: 105010.
[http://dx.doi.org/10.1016/j.bioorg.2021.105010] [PMID: 34102519]
[28]
Xiao ZP, Peng ZY, Dong JJ, et al. Synthesis, molecular docking and kinetic properties of β-hydroxy-β-phenylpropionyl-hydroxamic acids as Helicobacter pylori urease inhibitors. Eur J Med Chem 2013; 68: 212-21.
[http://dx.doi.org/10.1016/j.ejmech.2013.07.047] [PMID: 23974021]
[29]
Khan A, Hashim J, Arshad N, et al. Dihydropyrimidine based hydrazine dihydrochloride derivatives as potent urease inhibitors. Bioorg Chem 2016; 64: 85-96.
[http://dx.doi.org/10.1016/j.bioorg.2015.12.007] [PMID: 26771129]
[30]
Yang Y, Su M, Zhang X, Liu Q, He Z, Xu C. Developing potential Helicobacter pylori urease inhibitors from novel oxoindoline derivatives: Synthesis, biological evaluation and in silico study. Bioorg Med Chem Lett 2018; 28(19): 3182-6.
[31]
Fan T, Guo X, Zeng Q, et al. Synthesis and structure-activity relationship of palmatine derivatives as a novel class of antibacterial agents against Helicobacter pylori. Molecules 2020; 25(6): 1352.
[http://dx.doi.org/10.3390/molecules25061352] [PMID: 32188132]
[32]
Richter MF, Drown BS, Riley AP, et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 2017; 545(7654): 299-304.
[http://dx.doi.org/10.1038/nature22308] [PMID: 28489819]
[33]
Sohrabi M, Nazari Montazer M, Farid SM, et al. Design and synthesis of novel nitrothiazolacetamide conjugated to different thioquinazolinone derivatives as anti-urease agents. Sci Rep 2022; 12(1): 2003.
[http://dx.doi.org/10.1038/s41598-022-05736-4] [PMID: 35132095]
[34]
Imran M, Waqar S, Ogata K, et al. Identification of novel bacterial urease inhibitors through molecular shape and structure based virtual screening approaches. RSC Advances 2020; 10(27): 16061-70.
[http://dx.doi.org/10.1039/D0RA02363A] [PMID: 35493653]
[35]
Wang X, Song K, Li L, Chen L. Structure-based drug design strategies and challenges. Curr Top Med Chem 2018; 18(12): 998-1006.
[http://dx.doi.org/10.2174/1568026618666180813152921] [PMID: 30101712]
[36]
Jones G, Jindal A, Ghani U, et al. Elucidation of protein function using computational docking and hotspot analysis by ClusPro and FTMap. Acta Crystallogr D Struct Biol 2022; 78(6): 690-7.
[http://dx.doi.org/10.1107/S2059798322002741] [PMID: 35647916]
[37]
Brenke R, Kozakov D, Chuang GY, et al. Fragment-based identification of druggable ‘hot spots’ of proteins using Fourier domain correlation techniques. Bioinformatics 2009; 25(5): 621-7.
[http://dx.doi.org/10.1093/bioinformatics/btp036] [PMID: 19176554]
[38]
Kozakov D, Grove LE, Hall DR, et al. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nat Protoc 2015; 10(5): 733-55.
[http://dx.doi.org/10.1038/nprot.2015.043] [PMID: 25855957]
[39]
Ngan CH, Hall DR, Zerbe B, Grove LE, Kozakov D, Vajda S. FTSite: high accuracy detection of ligand binding sites on unbound protein structures. Bioinformatics 2012; 28(2): 286-7.
[http://dx.doi.org/10.1093/bioinformatics/btr651] [PMID: 22113084]
[40]
Jabri E, Carr M, Hausinger R, Karplus P. The crystal structure of urease from Klebsiella aerogenes. Science 1995; 268(5213): 998-1004.
[41]
Balasubramanian A, Ponnuraj K. Crystal structure of the first plant urease from jack bean: 83 years of journey from its first crystal to molecular structure. J Mol Biol 2010; 400(3): 274-83.
[http://dx.doi.org/10.1016/j.jmb.2010.05.009] [PMID: 20471401]
[42]
Cunha ES, Chen X, Sanz-Gaitero M, Mills DJ, Luecke H. Cryo-EM structure of Helicobacter pylori urease with an inhibitor in the active site at 2.0 Å resolution. Nat Commun 2021; 12(1): 230.
[http://dx.doi.org/10.1038/s41467-020-20485-6] [PMID: 33431861]
[43]
Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. Edited by FE Cohen J Mol Biol 1997; 267(3): 727-48.
[http://dx.doi.org/10.1006/jmbi.1996.0897] [PMID: 9126849]
[44]
Mooij WTM, Verdonk ML. General and targeted statistical potentials for protein-ligand interactions. Proteins 2005; 61(2): 272-87.
[http://dx.doi.org/10.1002/prot.20588] [PMID: 16106379]

Rights & Permissions Print Cite
Article Metrics
27
2
© 2024 Bentham Science Publishers | Privacy Policy